Skip to main content
BNTC logo

BNTC · Benitec Biopharma Inc.

Track BNTC — free
$12.19 -0.03 (-0.25%) At close · Sep 11
Market Cap
$418.78M
Shares
34.35M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.19 Open$12.38 Day$12.12–12.51 52W close$10.06–16.52 Avg vol 30d157K Short int2.2M · 6.4% float · 14.3d Short vol73% Last earningsMay 14, 2026 DataJul 2023–Sep 2026 Filing10-Q · May 14

Raw chart and full-history price indicators begin at the captured split on Jul 26, 2023; bars on opposite sides are not compared.

Up next

filed May 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$41.54M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
$184.76M
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+27.9%
Year over year · more shares
Price change (1Y)
-8.4%
Trailing year
Short interest
6.4%
Latest settlement · 14.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +1%
above
Price vs 50-day avg −4%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 33%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −3%
trailing
6-month return +11%
trailing
YTD return −10%
this year
Relative strength −7%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.45% of float · ▲ +5.1% MoM · 14.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
86 holders — near 3-yr high, broad support
Squeeze score 76
high risk · 0–100
Fundamentals
Weak
Revenue growth −42%
Y/Y
EPS growth +14%
Y/Y
Free cash flow $-23.6M
Quant / Vol
risk profile
Very High
Volatility 58%
annualized · 1-yr
Max drawdown −39%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+1% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
33% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.45% of float · ▲ +5.1% MoM · 14.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
86 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10 Now $12 · 33% Range high $17
vs 200-day avg +1% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BNTC
Benitec Biopharma Inc.
this stock
$418.78M -9.5% -42.2% 6.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
$130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
$61.60B +17.1% 2.0%
MRNA
Moderna, Inc.
$57.48B +388.2% +4.3% 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
86
% held
96.5%
Net QoQ
+746.2K sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
92
View
Short & Settlement
Short Interest Rising
Shares short
2.2M
Days to cover
14.3d
Change
+107.2K sh
View
Short Volume
Short vol %
73%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
4.9K
Value
$61.7K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
29.1%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$59.0K
Net income (FY)
$-37.9M
EPS diluted
$-1.05
View
Filings
SEC Filings
Latest
8-K
Filed
May 29, 2026
This year
6
View
Exempt Offerings
Offering
$40.0M
Filed
Apr 25, 2024
View
Earnings & Events
Earnings Calls
Last call
May 14, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jul 26, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
BNTC -2.0% -3.0% +11.0% +0.2% -9.5%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -0.9% -1.2% -6.8% +0.5% -21.6%
Key facts CIK 1808898 CUSIP 08205P209 13F (30d) 52 filings 52 filers Visit website Investor relations